Pharmaceutical Intermediate Manufacturer Interprets Lilly's Financial Report for the First Half of 2025: Tirzepatide Performs Impressively, Driving Performance Growth
Publish Time:
2025-08-21
On August 7, 2025, Lilly released its financial report for the first half of 2025, showing strong growth momentum, with the outstanding performance of tirzepatide-related products particularly notable, which also brings positive signals to the tirzepatide intermediate field.
The financial report shows that Lilly's revenue in the first half of the year increased by 41% year-on-year, reaching 28.286 billion USD. Based on this strong performance, the company raised the median full-year revenue guidance for 2025 by 1.5 billion USD to a range of 60 billion to 62 billion USD; meanwhile, the EPS guidance was raised to a range of 20.85–22.10 USD, and the Non-GAAP adjusted EPS guidance was raised to a range of 21.75–23.00 USD. This series of upward revisions is strongly supported by tirzepatide-related products' contribution to overall performance.
From the regional market perspective, revenue in the US market was 19.3 billion USD, up 43% year-on-year; the European market was 4.96 billion USD, up 74%; the Japanese market was 900 million USD, up 11%; the Chinese market was 900 million USD, up 20%; and other markets totaled 2.18 billion USD, up 7%. Growth across these regions has provided broad space for the sales of tirzepatide-related products, thereby driving demand for tirzepatide intermediates.
In the diabetes segment, four products—Trulicity (dulaglutide), Mounjaro (diabetes version of tirzepatide), Humalog (lispro insulin), and Jardiance (empagliflozin)—together contributed 13.97 billion USD in revenue, accounting for 49% of Lilly's total revenue. Among them, Mounjaro (diabetes version of tirzepatide) performed outstandingly, with an 85% year-on-year increase to 9 billion USD; the weight-loss version of tirzepatide (Zepbound) achieved sales of 5.69 billion USD, up 223%. The rapid growth of these two tirzepatide products fully reflects the market's recognition and strong demand, which will undoubtedly increase the procurement volume of tirzepatide intermediates.
More notably, Lilly's GLP-1 products' prescription volume share in the US market exceeded that of Novo Nordisk's GLP-1 products in the first quarter of 2025 (53.3% vs 46.1%), and the gap has since widened to 57.0% vs 42.5%. This leading market share advantage further consolidates the market position of tirzepatide-related products and indicates a very broad market prospect for tirzepatide intermediates.
Regarding pipeline progress, good news has also come from tirzepatide. The SURPASS CVOT study of tirzepatide targeting patients with type 2 diabetes combined with cardiovascular disease has achieved positive results. This research progress will help enhance the competitiveness and market penetration of tirzepatide-related products, continuously driving demand growth for tirzepatide intermediates.
In summary, in Lilly's excellent performance in the first half of 2025, tirzepatide-related products played an indispensable role. Their strong growth momentum and good market performance bring huge development opportunities to the field of tirzepatide intermediates.
Intermediates, side chains, and fragments required for synthesizing tirzepatide, manufacturer: CongenPharma
| Serial Number | Product Name | CAS Number |
| 1 | 20-(tert-butoxy)-20-oxoicosanoic acid | 683239-16-9 |
| 2 | tBuO-C20-L-Glu-OtBu | 1119061-70-9 |
| 3 | tBuO-C20-L-Glu(AEEA-AEEA-OH)-OtBu | 1188328-37-1 |
| 4 | Fmoc-L-Lys[tBuO-C20-L-Glu(AEEA-AEEA)-OtBu]-OH | 2915356-76-0 |
| 5 | Fmoc-Glu(OtBu)-Aib-OH | 866044-63-5 |
| 6 | Tirzepatide Frag AA30-39 | 2656383-23-0 |
| 7 | Tirzepatide Frag AA22-29 | 2461524-68-3 |
| 8 | Tirzepatide Frag AA15-21 | 2656383-24-1 |
| 9 | Tirzepatide Frag AA1-14 | 2656383-25-2 |
| 10 | Fmoc-Ile-Aib-OH | 2171139-20-9 |
| 11 | Fmoc-Tyr(tBu)-Aib-OH | 2645414-22-6 |
| 12 | Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-OH | 2682040-93-1 |
